AZ/Daiichi's possible breast cancer blockbuster gets fast US...

The FDA has granted a priority review for AstraZeneca and Daiichi Sankyo’s potential breast cancer blockbuster trastuzumab deruxtecan, setting up a possible launch as early as Q2 next year.

Astellas maintains lead over Daiichi Sankyo with CHMP okay f...

Daiichi Sankyo’s pexidartinib is first FDA-approved drug for...

/* Style Definitions */ table.MsoNormalTable {mso-style-name:"Table Normal"; mso-tstyle-rowband-size:0; mso-tstyle-colband-size:0;

Daiichi waits on FDA as AML drug quizartinib approved in Jap...

The Japanese regulator has approved Daiichi Sankyo’s quizartinib for certain patients with acute myeloid leukaemia (AML), amid doubts over the outcome of a regulatory review in the US.

Daiichi Sankyo in talks over OTC unit sale - reports

Daiichi Sankyo is in talks with several companies over a sale of its over-the-counter (OTC) business, according to press reports.

Oncology round-up: AZ and Daiichi score key trial win with b...

AZ and Daiichi Sankyo announced positive top-line results from the pivotal phase 2 DESTINY-Breast01 trial of trastuzumab deruxtecan, an antibody-drug conjugate, in patients with an advanced